Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy

Clinical Cancer Research

Volumn 7, Issue 6, 2001, Pages 1497-1504

  Harris, L N ^a   Yang, Li ^b   Liotcheva, Vlayka ^b   Pauli, Samuel ^b   Colvin, O Michael ^c   Hsieh, Tao Shih ^d   Iglehart, James Dirk ^e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Department of Medicine ^*  (United States)

^c Department of Surgery   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIDERMAL GROWTH FACTOR; ETOPOSIDE; ONCOPROTEIN; TRASTUZUMAB;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL STRAIN 3T3; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME INDUCTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL NUCLEUS; CYCLOPHOSPHAMIDE; DNA; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; ETOPOSIDE; FEMALE; HUMANS; MICE; NUCLEIC ACID SYNTHESIS INHIBITORS; PROTEIN BINDING; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0034900175     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Polychemotherapy for early breast cancer: An overview of the randomized trials
2. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer
3. ErbB2 amplification in breast cancer with a high rate of proliferation
4. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer
5. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer
6. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: NSABP B-15
7. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
8. Induction of chemotherapy sensitivity in MCF-7 breast cancer cells by heregulin
9. The erbB-2 mitogenic signaling pathway: Tyrosine phosphorylation of phospholipase C-γ and GTPase-activating protein does not correlate with erbB-2 mitogenic potency
10. The type I growth factor receptors in human breast cancer
11. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
12. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines
13. Novel topologically knotted DNA from bacteriophage P4 capsids: Studies with DNA topoisomerases
14. Decatenation of kinetoplast DNA by topoisomerases
15. DNA damage by antitumor acridines mediated by mammalian topoisomerase II
16. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors
17. DNA topoisomerase poisons as antitumor drugs
18. Complex response of breast epithelial cell lines to topoisomerase inhibitors
19. Prognostic importance of C-erbB-2 expression in breast cancer
20. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
21. Moving on DNA double helix through another by a type II DNA topoisomerase: The story of a simple molecular machine
22. Topoisomerase II α co-amplification with erbB-2 in human primary breast cancer and breast cancer cell lines: Relationship to mAMSA and mitoxantrone sensitivity
23. Expression of MDR1, GST-π and topoisomerase II as an indicator of clinical response to Adriamycin
24. Expression of topoisomerase IIα is associated with rapid cell proliferation, aneuploidy and c-erbB2 overexpression in breast cancer
25. Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer
26. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
27. C-erbB-2 in serum of patients with breast cancer
28. Elevated DNA polymerase α, DNA polymerase β, and DNA topoisomerase II in a melphalan-resistant rhabdomosarcoma xenograft that is cross-resistant to nitrosoureas and toptecan
29. Alkylating agents and platinum antitumor compounds
30. DNA topoisomerases as repair enzymes: Mechanism(s) of action and regulation by p53
31. Induction of alkylator (melphalan) resistance in HL60 cells is accompanied by increased levels of topoisomerase II expression and function
32. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
33. p185c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between and oncogenic receptor tyrosine kinase and drug-induced DNA repair
34. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression